Equity Profile

JNJ

Johnson & Johnson

Health CarePharmaceuticals$620.5B

Jul15Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Johnson & Johnson (JNJ) is a leading global healthcare company that develops pharmaceuticals, medical devices, and consumer health products. With a market cap of $621 billion, it plays a crucial role in the healthcare sector, focusing on innovation and addressing various health challenges.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$2.84

Revenue

Revenue reflects the company's overall sales performance and growth potential, making it essential for assessing business health.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1-2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Johnson & Johnson to report solid earnings this quarter, with a consensus EPS of $2.84 and revenue of $25.0 billion. The company has consistently beaten EPS estimates in recent quarters.

Bull Case

If JNJ continues its trend of beating EPS estimates, it could see a significant stock price increase, especially if revenue growth is strong.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the high implied volatility.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$25.0B

Revenue reflects the company's overall sales performance and growth potential, making it essential for assessing business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will JNJ's EPS exceed the consensus estimate of $2.84?

A beat on EPS would reinforce the company's strong performance and could drive the stock higher.

What guidance will management provide regarding future revenue growth?

Investors will closely watch for any signs of slowing growth, which could impact stock sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

While the consensus expects steady growth, JNJ's diverse product portfolio and recent innovations may lead to stronger-than-expected performance.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 100% beat rate in the last eight quarters.

Options pricing suggests a higher expected move than historical averages, indicating potential for a larger reaction.

Recent insider selling could suggest caution, but it may also indicate confidence in the company's long-term strategy.

Key Risk

If revenue growth exceeds $25.4 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether JNJ can maintain its growth trajectory amidst increasing competition and market pressures.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $2.70 would confirm the bear case, signaling potential weakness.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If JNJ beats expectations, history suggests a potential stock increase of around 1.22%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 1.22%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations.
2Management's outlook on market competition and pricing pressures.
3Details on cost management strategies and their impact on margins.
4Insights into consumer health trends and their effects on sales.
5Any commentary on regulatory challenges or opportunities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$2.84

Revenue

Revenue reflects the company's overall sales performance and growth potential, making it essential for assessing business health.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1-2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If JNJ continues its trend of beating EPS estimates, it could see a significant stock price increase, especially if revenue growth is strong.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the high implied volatility.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$25.0B

Revenue reflects the company's overall sales performance and growth potential, making it essential for assessing business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will JNJ's EPS exceed the consensus estimate of $2.84?

A beat on EPS would reinforce the company's strong performance and could drive the stock higher.

What guidance will management provide regarding future revenue growth?

Investors will closely watch for any signs of slowing growth, which could impact stock sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

While the consensus expects steady growth, JNJ's diverse product portfolio and recent innovations may lead to stronger-than-expected performance.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 100% beat rate in the last eight quarters.

Options pricing suggests a higher expected move than historical averages, indicating potential for a larger reaction.

Recent insider selling could suggest caution, but it may also indicate confidence in the company's long-term strategy.

Key Risk

If revenue growth exceeds $25.4 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether JNJ can maintain its growth trajectory amidst increasing competition and market pressures.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $2.70 would confirm the bear case, signaling potential weakness.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If JNJ beats expectations, history suggests a potential stock increase of around 1.22%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 1.22%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations.
2Management's outlook on market competition and pricing pressures.
3Details on cost management strategies and their impact on margins.
4Insights into consumer health trends and their effects on sales.
5Any commentary on regulatory challenges or opportunities.